Analyzing Acrivon Therapeutics (NASDAQ:ACRV) and Addex Therapeutics (OTCMKTS:ADDXF)

Addex Therapeutics (OTCMKTS:ADDXF) and Acrivon Therapeutics (NASDAQ:ACRV) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Addex Therapeutics and Acrivon Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Addex Therapeutics	0	0	0	0	0.00
Acrivon Therapeutics	0	0	6	0	3.00

Acrivon Therapeutics has a consensus target price of $23.67, indicating a potential upside of 270.95%. Given Acrivon Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Acrivon Therapeutics is more favorable than Addex Therapeutics.

Institutional & Insider Ownership

71.6% of Acrivon Therapeutics shares are held by institutional investors. 8.5% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Addex Therapeutics and Acrivon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Addex Therapeutics	N/A	N/A	N/A
Acrivon Therapeutics	N/A	-47.95%	-43.73%

Risk and Volatility

Addex Therapeutics has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500.

Valuation & Earnings

This table compares Addex Therapeutics and Acrivon Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
Acrivon Therapeutics	N/A	N/A	-$60.39 million	($2.70)	-2.36

Summary

Acrivon Therapeutics beats Addex Therapeutics on 6 of the 8 factors compared between the two stocks.

About Addex Therapeutics

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.